Literature DB >> 20551326

Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival.

Danielle M Lapierre1, Natsuko Tanabe, Alexey Pereverzev, Martha Spencer, Ryan P P Shugg, S Jeffrey Dixon, Stephen M Sims.   

Abstract

Lysophosphatidic acid (LPA) is a bioactive phospholipid whose functions are mediated by multiple G protein-coupled receptors. We have shown that osteoblasts produce LPA, raising the possibility that it mediates intercellular signaling among osteoblasts and osteoclasts. Here we investigated the expression, signaling and function of LPA receptors in osteoclasts. Focal application of LPA elicited transient increases in cytosolic calcium concentration ([Ca(2+)](i)), with 50% of osteoclasts responding at approximately 400 nm LPA. LPA-induced elevation of [Ca(2+)](i) was blocked by pertussis toxin or the LPA(1/3) receptor antagonist VPC-32183. LPA caused sustained retraction of osteoclast lamellipodia and disrupted peripheral actin belts. Retraction was insensitive to VPC-32183 or pertussis toxin, indicating involvement of a distinct signaling pathway. In this regard, inhibition of Rho-associated kinase stimulated respreading after LPA-induced retraction. Real-time reverse transcription-PCR revealed transcripts encoding LPA(1) and to a lesser extent LPA(2), LPA(4), and LPA(5) receptor subtypes. LPA induced nuclear translocation of NFATc1 and enhanced osteoclast survival, effects that were blocked by VPC-32183 or by a specific peptide inhibitor of NFAT activation. LPA slightly reduced the resorptive activity of osteoclasts in vitro. Thus, LPA binds to at least two receptor subtypes on osteoclasts: LPA(1), which couples through G(i/o) to elevate [Ca(2+)](i), activate NFATc1, and promote survival, and a second receptor that likely couples through G(12/13) and Rho to evoke and maintain retraction through reorganization of the actin cytoskeleton. These findings reveal a signaling axis in bone through which LPA, produced by osteoblasts, acts on multiple receptor subtypes to induce pleiotropic effects on osteoclast activity and function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551326      PMCID: PMC2919141          DOI: 10.1074/jbc.M110.109322

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

Authors:  S C Manolagas
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

2.  Activation of P2Y but not P2X(4) nucleotide receptors causes elevation of [Ca2+]i in mammalian osteoclasts.

Authors:  A F Weidema; S J Dixon; S M Sims
Journal:  Am J Physiol Cell Physiol       Date:  2001-06       Impact factor: 4.249

3.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.

Authors:  T Ishizaki; M Uehata; I Tamechika; J Keel; K Nonomura; M Maekawa; S Narumiya
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

4.  Rho-dependent, Rho kinase-independent inhibitory regulation of Rac and cell migration by LPA1 receptor in Gi-inactivated CHO cells.

Authors:  Naotoshi Sugimoto; Noriko Takuwa; Kazuaki Yoshioka; Yoh Takuwa
Journal:  Exp Cell Res       Date:  2006-03-27       Impact factor: 3.905

5.  Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases.

Authors:  A Grey; T Banovic; D Naot; B Hill; K Callon; I Reid; J Cornish
Journal:  Endocrinology       Date:  2001-03       Impact factor: 4.736

Review 6.  Emerging medicinal roles for lysophospholipid signaling.

Authors:  Shannon E Gardell; Adrienne E Dubin; Jerold Chun
Journal:  Trends Mol Med       Date:  2006-01-10       Impact factor: 11.951

7.  Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior.

Authors:  J J Contos; N Fukushima; J A Weiner; D Kaushal; J Chun
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

Authors:  Marion David; Estelle Wannecq; Françoise Descotes; Silvia Jansen; Blandine Deux; Johnny Ribeiro; Claire-Marie Serre; Sandra Grès; Nathalie Bendriss-Vermare; Mathieu Bollen; Simone Saez; Junken Aoki; Jean-Sébastien Saulnier-Blache; Philippe Clézardin; Olivier Peyruchaud
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

9.  Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells.

Authors:  Lisa M Masiello; Joseph S Fotos; Deni S Galileo; Norman J Karin
Journal:  Bone       Date:  2006-02-17       Impact factor: 4.398

10.  Rho and Rac exert antagonistic functions on spreading of macrophage-derived multinucleated cells and are not required for actin fiber formation.

Authors:  S Ory; Y Munari-Silem; P Fort; P Jurdic
Journal:  J Cell Sci       Date:  2000-04       Impact factor: 5.285

View more
  21 in total

1.  Regulation of gene expression and subcellular protein distribution in MLO-Y4 osteocytic cells by lysophosphatidic acid: Relevance to dendrite outgrowth.

Authors:  Katrina M Waters; Jon M Jacobs; Marina A Gritsenko; Norman J Karin
Journal:  Bone       Date:  2011-02-26       Impact factor: 4.398

Review 2.  Lysophosphatidic Acid and Sphingosine-1-Phosphate: A Concise Review of Biological Function and Applications for Tissue Engineering.

Authors:  Bernard Y K Binder; Priscilla A Williams; Eduardo A Silva; J Kent Leach
Journal:  Tissue Eng Part B Rev       Date:  2015-07-14       Impact factor: 6.389

3.  Osteopontin signals through calcium and nuclear factor of activated T cells (NFAT) in osteoclasts: a novel RGD-dependent pathway promoting cell survival.

Authors:  Natsuko Tanabe; Benjamin D Wheal; Jiyun Kwon; Hong H Chen; Ryan P P Shugg; Stephen M Sims; Harvey A Goldberg; S Jeffrey Dixon
Journal:  J Biol Chem       Date:  2011-09-22       Impact factor: 5.157

4.  Effect of lysophosphatidic acid receptor inhibition on bone changes in ovariectomized mice.

Authors:  Beatriz Orosa; Paula Martínez; Antonio González; David Guede; José R Caeiro; Juan J Gómez-Reino; Carmen Conde
Journal:  J Bone Miner Metab       Date:  2014-07-04       Impact factor: 2.626

Review 5.  The roles of autotaxin/lysophosphatidic acid in immune regulation and asthma.

Authors:  Seung-Jae Kim; Hyung-Geun Moon; Gye Young Park
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-01-29       Impact factor: 4.698

Review 6.  Lysophosphatidic acid signalling in development.

Authors:  Xiaoyan Sheng; Yun C Yung; Allison Chen; Jerold Chun
Journal:  Development       Date:  2015-04-15       Impact factor: 6.868

7.  Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis.

Authors:  Pengxiu Cao; Yoshiro Aoki; Linda Badri; Natalie M Walker; Casey M Manning; Amir Lagstein; Eric R Fearon; Vibha N Lama
Journal:  J Clin Invest       Date:  2017-02-27       Impact factor: 14.808

8.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

9.  LPA Stimulates the Phosphorylation of p130Cas via Gαi2 in Ovarian Cancer Cells.

Authors:  Jeremy D Ward; Danny N Dhanasekaran
Journal:  Genes Cancer       Date:  2012-09

10.  Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.

Authors:  Marion David; Irma Machuca-Gayet; Junichi Kikuta; Penelope Ottewell; Fuka Mima; Raphael Leblanc; Edith Bonnelye; Johnny Ribeiro; Ingunn Holen; Rùben Lopez Vales; Pierre Jurdic; Jerold Chun; Philippe Clézardin; Masaru Ishii; Olivier Peyruchaud
Journal:  J Biol Chem       Date:  2014-01-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.